As it works to close a $40 million Series C round of financing, expressed RNAi drug developer Nucleonics is also weighing the possibility of floating its shares on the public market, President and CEO Robert Towarnicki told investors last week at the Acumen BioFin Rodman & Renshaw Healthcare Conference.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.